Bluebird says Ayrmid missed deadline for rival takeover bid

Bluebird says Ayrmid missed deadline for rival takeover bid

The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about $29 million upfront.

Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline - Pharmaceutical Technology

Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended deadline.

#Bluebird Bios Revenue Soars Over 350% as Company Dismisses Ayrmids Non-Binding Acquisition Proposal, Affirms C...

Bluebird Bio Reaffirms Commitment to Carlyle and SK Capital Amidst Unfulfilled Engagement with Ayrmid Ltd. Somerville, Mass.' In a recent announcement, bluebird bio, Inc. (NASDAQ: BLUE) has confirmed that Ayrmid Ltd. has failed to deliver a binding offer or secure necessary financing for the proposed acquisition, despite a period of extensive discussions that lasted three weeks, including an extension of the timeline for negotiations. This state…

Ayrmid misses deadline for detailed offer to top private equity bid for bluebird

A rival bid by Ayrmid for bluebird bio hasn't crossed the finish line, the biotech said, after failing to confirm financing by a Tuesday deadline. Ayrmid sought to top a February deal between bluebird and ...